Baidu
map

Nat Commun:可怕!这些基因竟会影响社交!或是孤独症的罪魁祸首!

2018-07-06 Ruthy,Zoe 转化医学网

孤独症(又称自闭症)是一种先天性神经系统疾病,临床表现包括社会交往沟通能力障碍、语言发育障碍、兴趣爱好比较狭窄、智能较差、行为活动刻板等。虽然孤独症的病因还不完全清楚,但目前的研究表明,遗传、感染与免疫和孕期理化因子刺激可能同孤独症的发病相关。有研究显示孤独症是一种多基因遗传病,但目前尚未有具体研究揭示孤独症的具体遗传因素。

孤独症(又称自闭症)是一种先天性神经系统疾病,临床表现包括社会交往沟通能力障碍、语言发育障碍、兴趣爱好比较狭窄、智能较差、行为活动刻板等。虽然孤独症的病因还不完全清楚,但目前的研究表明,遗传、感染免疫和孕期理化因子刺激可能同孤独症的发病相关。有研究显示孤独症是一种多基因遗传病,但目前尚未有具体研究揭示孤独症的具体遗传因素。

近期,剑桥大学临床医学院的研究人员在著名学术期刊《Nature Communications》发表的研究结果对孤独症的遗传病因有了更深入的解释,他们发现一些基因不仅与个人社交选择息息相关,还在个人孤独倾向的形成中发挥作用。

孤独症的重要表现之一就是社会隔离,因此,这些基因可能是孤独症真正的罪魁祸首。该研究以《Elucidating the genetic basis of social interaction and isolation》为题发表。

长期以来,科学家们普遍认为孤独症是在一定的遗传倾向性下,由环境致病因子诱发的疾病,但对具体的遗传因素的研究长期停滞不前。

在这项新研究中,研究人员在存储患者信息的英国生物银行公共数据库中进行搜索,在452,302名参与者中,他们以孤独症和定期参与社交活动为分类标准,进行全基因组关联研究分析,确定了产生相应影响的基因位点,同时对这些位点进行了测试。


孤独症或有孤独倾向参与者的社会活动

研究人员通过GWAS分离出15个可能与孤独感相关的基因组变异位点,具有这些特定变异的人比其他人更容易有孤独倾向。

而在这15个基因组变异位点中,有13个位点是早已确定会影响个人社交行为,与个人外出交流、参加集体活动的频率、积极性有关的位点!我们知道,孤独症的经典症状之一就是社会隔离!那么,这13个位点会不会是孤独症的根源呢?


变异位点表达富集对社会活动的影响

研究人员对这些变异位点进行深入的检测分析,发现在有孤独症或有孤独倾向的参与者中,这些变异位点在大脑控制情绪表达和行为的区域中出现了大量的表达富集,这些区域不仅是个体社会活动的控制中枢,也是孤独症患者常见的受损区域。

这些位点的大量表达进一步加深了孤独倾向,而在正常参与者中,这些正常位点的表达则有效促进了个体的社会活动。也就是说,这些可以影响个体社会活动的基因位点的变异,或是孤独症真正的罪魁祸首!

对此,研究人员进行了进一步的基因表达分析,确定13个基因组变异位点中,GPX1,C1QTNF4,C17orf58,MTCH2,BPTF,RP11-159N11.4,CRHR1-IT1和PLEKHM1的表达水平与孤独症的易感性相关。

因此,研究人员认为在孤独症的发生中基因起到了不可磨灭的作用,该研究结果为未来研究提供了遗传资源,以探索社会孤立的潜在可改变风险因素。但是目前的研究结果仅是基于个人自我报告的孤独或社交活动情况,因此,在结果得到确认之前需要进行更多的研究。

原始出处:

Felix R. Day,et al.Elucidating the genetic basis of social interaction and isolation.Nat Commun.03 July 2018

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1883159, encodeId=767f188315987, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Sun Feb 17 11:23:00 CST 2019, time=2019-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2087380, encodeId=90f2208e380a1, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Tue Dec 18 10:23:00 CST 2018, time=2018-12-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=330289, encodeId=11ea330289bd, content=学习了.谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=140, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Mon Jul 09 00:22:43 CST 2018, time=2018-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1603419, encodeId=3fbc160341953, content=<a href='/topic/show?id=657ce391325' target=_blank style='color:#2F92EE;'>#社交#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73913, encryptionId=657ce391325, topicName=社交)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=004519034290, createdName=fengyi818, createdTime=Sun Jul 08 11:23:00 CST 2018, time=2018-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=329808, encodeId=b43632980883, content=了解一下.谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=141, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/23/2f51002e1349ccda5be11c1eea1e1e60.jpg, createdBy=a22097948, createdName=天地飞扬, createdTime=Fri Jul 06 20:36:06 CST 2018, time=2018-07-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=329799, encodeId=ac2c329e9948, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=160, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82311653708, createdName=医者仁心5538, createdTime=Fri Jul 06 20:31:54 CST 2018, time=2018-07-06, status=1, ipAttribution=)]
    2019-02-17 liye789132251
  2. [GetPortalCommentsPageByObjectIdResponse(id=1883159, encodeId=767f188315987, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Sun Feb 17 11:23:00 CST 2019, time=2019-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2087380, encodeId=90f2208e380a1, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Tue Dec 18 10:23:00 CST 2018, time=2018-12-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=330289, encodeId=11ea330289bd, content=学习了.谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=140, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Mon Jul 09 00:22:43 CST 2018, time=2018-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1603419, encodeId=3fbc160341953, content=<a href='/topic/show?id=657ce391325' target=_blank style='color:#2F92EE;'>#社交#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73913, encryptionId=657ce391325, topicName=社交)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=004519034290, createdName=fengyi818, createdTime=Sun Jul 08 11:23:00 CST 2018, time=2018-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=329808, encodeId=b43632980883, content=了解一下.谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=141, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/23/2f51002e1349ccda5be11c1eea1e1e60.jpg, createdBy=a22097948, createdName=天地飞扬, createdTime=Fri Jul 06 20:36:06 CST 2018, time=2018-07-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=329799, encodeId=ac2c329e9948, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=160, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82311653708, createdName=医者仁心5538, createdTime=Fri Jul 06 20:31:54 CST 2018, time=2018-07-06, status=1, ipAttribution=)]
    2018-12-18 liuli5079
  3. [GetPortalCommentsPageByObjectIdResponse(id=1883159, encodeId=767f188315987, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Sun Feb 17 11:23:00 CST 2019, time=2019-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2087380, encodeId=90f2208e380a1, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Tue Dec 18 10:23:00 CST 2018, time=2018-12-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=330289, encodeId=11ea330289bd, content=学习了.谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=140, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Mon Jul 09 00:22:43 CST 2018, time=2018-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1603419, encodeId=3fbc160341953, content=<a href='/topic/show?id=657ce391325' target=_blank style='color:#2F92EE;'>#社交#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73913, encryptionId=657ce391325, topicName=社交)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=004519034290, createdName=fengyi818, createdTime=Sun Jul 08 11:23:00 CST 2018, time=2018-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=329808, encodeId=b43632980883, content=了解一下.谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=141, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/23/2f51002e1349ccda5be11c1eea1e1e60.jpg, createdBy=a22097948, createdName=天地飞扬, createdTime=Fri Jul 06 20:36:06 CST 2018, time=2018-07-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=329799, encodeId=ac2c329e9948, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=160, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82311653708, createdName=医者仁心5538, createdTime=Fri Jul 06 20:31:54 CST 2018, time=2018-07-06, status=1, ipAttribution=)]
    2018-07-09 1209e435m98(暂无昵称)

    学习了.谢谢分享

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1883159, encodeId=767f188315987, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Sun Feb 17 11:23:00 CST 2019, time=2019-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2087380, encodeId=90f2208e380a1, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Tue Dec 18 10:23:00 CST 2018, time=2018-12-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=330289, encodeId=11ea330289bd, content=学习了.谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=140, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Mon Jul 09 00:22:43 CST 2018, time=2018-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1603419, encodeId=3fbc160341953, content=<a href='/topic/show?id=657ce391325' target=_blank style='color:#2F92EE;'>#社交#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73913, encryptionId=657ce391325, topicName=社交)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=004519034290, createdName=fengyi818, createdTime=Sun Jul 08 11:23:00 CST 2018, time=2018-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=329808, encodeId=b43632980883, content=了解一下.谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=141, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/23/2f51002e1349ccda5be11c1eea1e1e60.jpg, createdBy=a22097948, createdName=天地飞扬, createdTime=Fri Jul 06 20:36:06 CST 2018, time=2018-07-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=329799, encodeId=ac2c329e9948, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=160, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82311653708, createdName=医者仁心5538, createdTime=Fri Jul 06 20:31:54 CST 2018, time=2018-07-06, status=1, ipAttribution=)]
    2018-07-08 fengyi818
  5. [GetPortalCommentsPageByObjectIdResponse(id=1883159, encodeId=767f188315987, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Sun Feb 17 11:23:00 CST 2019, time=2019-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2087380, encodeId=90f2208e380a1, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Tue Dec 18 10:23:00 CST 2018, time=2018-12-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=330289, encodeId=11ea330289bd, content=学习了.谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=140, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Mon Jul 09 00:22:43 CST 2018, time=2018-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1603419, encodeId=3fbc160341953, content=<a href='/topic/show?id=657ce391325' target=_blank style='color:#2F92EE;'>#社交#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73913, encryptionId=657ce391325, topicName=社交)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=004519034290, createdName=fengyi818, createdTime=Sun Jul 08 11:23:00 CST 2018, time=2018-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=329808, encodeId=b43632980883, content=了解一下.谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=141, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/23/2f51002e1349ccda5be11c1eea1e1e60.jpg, createdBy=a22097948, createdName=天地飞扬, createdTime=Fri Jul 06 20:36:06 CST 2018, time=2018-07-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=329799, encodeId=ac2c329e9948, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=160, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82311653708, createdName=医者仁心5538, createdTime=Fri Jul 06 20:31:54 CST 2018, time=2018-07-06, status=1, ipAttribution=)]
    2018-07-06 天地飞扬

    了解一下.谢谢分享!

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1883159, encodeId=767f188315987, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Sun Feb 17 11:23:00 CST 2019, time=2019-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2087380, encodeId=90f2208e380a1, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Tue Dec 18 10:23:00 CST 2018, time=2018-12-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=330289, encodeId=11ea330289bd, content=学习了.谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=140, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Mon Jul 09 00:22:43 CST 2018, time=2018-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1603419, encodeId=3fbc160341953, content=<a href='/topic/show?id=657ce391325' target=_blank style='color:#2F92EE;'>#社交#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73913, encryptionId=657ce391325, topicName=社交)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=004519034290, createdName=fengyi818, createdTime=Sun Jul 08 11:23:00 CST 2018, time=2018-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=329808, encodeId=b43632980883, content=了解一下.谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=141, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/23/2f51002e1349ccda5be11c1eea1e1e60.jpg, createdBy=a22097948, createdName=天地飞扬, createdTime=Fri Jul 06 20:36:06 CST 2018, time=2018-07-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=329799, encodeId=ac2c329e9948, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=160, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82311653708, createdName=医者仁心5538, createdTime=Fri Jul 06 20:31:54 CST 2018, time=2018-07-06, status=1, ipAttribution=)]
    2018-07-06 医者仁心5538

    学习了

    0

相关资讯

精准诊疗或助儿童摆脱“孤独”

有这样一群特殊的儿童,在西方被称为“星星的孩子”——像星星一样,孤独地闪烁在另一个世界。他们目光澄亮,却对人视而不见;听觉灵敏,却对父母的呼唤充耳不闻;发声正常,却不与他人交流;常被认为是智障,却又常在部分领域能力超常……他们就是孤独症儿童。 孤独症也叫自闭症,是一种由于神经系统失调导致的发育障碍性疾病。由于病因十分复杂且至今尚未明确,一度被认为是“无法治愈”的绝症。 为探讨孤

Pediatrics:产前暴露于哮喘药可增加后代孤独症风险

产前暴露于哮喘药可增加后代自闭症风险1月6日在线发表在儿科杂志上的,一项新的研究表明,产前暴露于常用的哮喘药物可能会增加自闭症谱系障碍(又称孤独症谱系障碍,Autism Spectrum Disorder ,ASD)的风险。研究人员发现,在孕期,孕妇暴露于β-2肾上腺素受体激动剂(B2AR)与自闭症风险增加有关, 且该风险在所有孕期是相似的。然而,该论文的第一作者,来自美国宾夕法尼亚州费城,德雷塞

孤独症,双相情感和精神分裂症的遗传相似性

通过检查脑组织,研究人员发现某些精神疾病间具有相似之处,包括孤独症和精神分裂症。研究人员说,具体来说,在患有自闭症,精神分裂症和躁郁症的人群中发现了一些相似的基因表达模式。基因表达是指细胞将基因指令转化为蛋白质。"这些发现提供了这些疾病的分子、病理特征,这是向前迈出的一大步,"资深研究作者Daniel Geschwind说。"现在的主要挑战是了解这些变化是如何产生的,"加州大学洛杉矶分校自闭症研究

孤独症:目前终生无法治愈 四岁前是更佳干预期

4月1日,可容纳上***的首都师范大学活动中心进行了一场世界孤独症日公益展演,当天,很多孤独症患者和他们的家长来到现场。在3个多小时的活动中,会场一直很嘈杂,甚至突然会出现尖叫声。

Neurosci Biobehav Rev:精神分裂症谱系与孤独症谱系患者表现出相似多感觉时间整合缺陷

精神分裂症和孤独症是两种严重的神经发育性疾病,它们有很多相似的临床症状,如社会认知缺损、社交互动障碍等。最新的研究提示,这两种疾病可能处在同一个神经发育性疾病的连续体中。

Oncotarget:孤独症也是免疫性疾病?

近年来,越来越多的研究表明神经、精神类疾病如精神分裂症、阿兹海默症的发生与免疫系统的异常有关。孤独症是一类以刻板动作,社交障碍为核心症状的儿童神经发育性疾病,然而,在儿童孤独症患者中是否有哪些免疫系统的异常,并无系统性的研究。近日来自于四川大学华西第二医院许文明教授课题组与西南交通大学临床医院谢江教授的一项合作研究,针对孤独症儿童的免疫特性及与孤独症儿童的行为异常的关系进行了系统的研究,为这一问题

Baidu
map
Baidu
map
Baidu
map